Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease.
about
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltrationImipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effectsPopulation pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.Pharmacokinetics of meropenem in patients with intra-abdominal infections.Comparative pharmacokinetics of the carbapenems: clinical implications.Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenemEfficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.Pharmacokinetic and pharmacodynamic properties of meropenem.An Open, Randomized, Single-Center, Crossover Pharmacokinetic Study of Meropenem after Intraperitoneal and Intravenous Administration in Patients Receiving Automated Peritoneal Dialysis.Pharmacokinetic study of meropenem in healthy beagle dogs receiving intermittent hemodialysis.Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients.Plasma pharmacokinetics and urine concentrations of meropenem in ewes.Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.Outcome evaluation of an intervention to improve the effective and safe use of meropenem.Cyst infection in autosomal dominant polycystic kidney disease: penetration of meropenem into infected cysts
P2860
Q24620193-07ECA516-23EA-404F-B204-8EF03EA8D8C5Q28260317-4A0CECF6-37CB-44F5-BA4D-7041C3DDC3C4Q30316322-7E00C854-465B-4345-BADA-0E6903B676B4Q33697160-D0EB2AE6-A6A0-4BA5-BB9E-C48A8126C731Q33697176-D7637C6A-FCD6-4BBE-959C-C1DBE0477FD7Q33747920-B1DD1094-3620-418B-B071-9C0440A92EADQ34053776-3E4ADEA1-D8E9-4ADA-9DA4-78B59C98ECBAQ35817800-8699B10A-4530-4ACD-9D3D-7C3E701B4F4FQ36744822-AF87ADE1-02A0-4683-ACE1-15951A881CA0Q36915096-FAF22FC4-1F77-45E0-A95F-E67F2B281B65Q37247125-F998C21F-6F22-43D9-A5FE-2E6CD6B37C81Q39592184-088948D5-E9DC-4B01-8B38-1BCCFC2A7B8BQ39682907-6555DC0C-8036-41F4-9FE6-EE314BE34579Q40441668-B0E93D68-12ED-43E5-927E-5D937D65A89AQ43962798-634FC831-7914-4BFB-9D7D-5911E70F4756Q44783360-87DB6EAC-F1A2-4234-9E7D-1E000A11BC61Q48139759-0D0219C5-57B8-4405-BCE7-0E9DA91F61D1Q50696325-083437AE-D1FC-4444-B477-CBE9ECD913B7Q57809501-FA80823E-7CF2-4951-9025-91E105ED3223
P2860
Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Pharmacokinetics of meropenem ...... with end-stage renal disease.
@ast
Pharmacokinetics of meropenem ...... with end-stage renal disease.
@en
type
label
Pharmacokinetics of meropenem ...... with end-stage renal disease.
@ast
Pharmacokinetics of meropenem ...... with end-stage renal disease.
@en
prefLabel
Pharmacokinetics of meropenem ...... with end-stage renal disease.
@ast
Pharmacokinetics of meropenem ...... with end-stage renal disease.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of meropenem ...... with end-stage renal disease.
@en
P2093
P2860
P304
P356
10.1128/AAC.37.2.229
P407
P577
1993-02-01T00:00:00Z